Biogen (BIIB) PT Raised to $408 at Cowen

Cowen raised its price target on Biogen (NASDAQ: BIIB) to $408.00 (from $338.00) while maintaining an Outperform rating.

Analyst Eric Schmidt highlighted that the MS franchise is steady while Spinraza sales were strong as the drug's ex-U.S. launch has accelerated.

You May Also Be Interested In

• CAVA Group Inc (CAVA) PT Lowered to $80 at JPMorgan, Overweight Rating Maintained
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy
• Hillman Solutions (HLMN) Reiterated at Buy by Stifel - M&A Growth Potential Undervalued